

Presentation of Xbrane Biopharma's interim report January – September 2022 on October 28, 2022

Xbrane Biopharma AB, (publ) ("Xbrane" eller "Bolaget") (Nasdaq Stockholm: XBRANE) today hosted a teleconference for investors, analysts and media.

Martin Åmark, CEO, and Anette Lindqvist, CFO/IR, presented the interim report January – September 2022, followed by a Q&A session.

As some technical issues were experienced pls follow the link to see the recorded version of the presentation.

Please follow the link below:

<https://edge.media-server.com/mmc/p/jx8bzgzs>

Contacts

Martin Åmark, CEO

M: +46 76 309 37 77

E: martin.amark@xbrane.com

Anette Lindqvist, CFO/IR

M: +46 76 325 60 90

E: anette.lindqvist@xbrane.com

About Us

Xbrane Biopharma AB develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane has a portfolio of biosimilar candidates targeting EUR 53 billion in estimated annual peak sales of the respective reference products. The lead candidate Ximluci® is under registration in Europe with a planned launch during the first quarter 2023. Xbrane's head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit www.xbrane.com

Attachments

[Presentation of Xbrane Biopharma's interim report January – September 2022 on October 28, 2022](#)